Study of Radiolabeled Danicopan in Healthy Male Participants
Study Identifier:
ACH471-005
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: [14C]-Danicopan
Date
Sep 2017 - Oct 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Male
Age: 18 - 55 Years
Requirements Information
Sex
Male
Age
18 - 55 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: [14C]-Danicopan
Date
Sep 2017 - Oct 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Male
Age: 18 - 55 Years years
Requirements Information
Protocol Summary
This was an open-label study to evaluate the absorption, distribution, metabolism, and excretion of radioactivity in healthy male participants following a single 150-milligram (mg) oral dose of carbon-14 (\[14C\])-ACH-014447 (\[14C\])-danicopan) containing approximately 100 microcuries (µCi) of \[14C\].
Trial Locations
Location
Status
Location
Clinical Trial Site
Auckland, New Zealand
Status
N/A